MediWound Ltd. (NASDAQ:MDWD - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of MediWound in a research report issued on Thursday, May 22nd. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will earn ($0.55) per share for the quarter, up from their prior estimate of ($0.66). HC Wainwright currently has a "Buy" rating and a $31.00 price target on the stock. The consensus estimate for MediWound's current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for MediWound's Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.63) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.60) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($0.82) EPS and FY2029 earnings at $1.13 EPS.
MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.58. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The company had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. During the same quarter last year, the company earned ($1.05) earnings per share.
Several other analysts also recently weighed in on MDWD. Craig Hallum assumed coverage on MediWound in a research report on Friday, February 28th. They issued a "buy" rating and a $39.00 price objective for the company. Alliance Global Partners started coverage on shares of MediWound in a report on Friday, May 2nd. They set a "buy" rating and a $25.00 price target for the company. Finally, Wall Street Zen raised shares of MediWound to a "sell" rating in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, MediWound presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.25.
Check Out Our Latest Stock Report on MediWound
MediWound Trading Down 0.7%
Shares of NASDAQ:MDWD traded down $0.15 on Monday, reaching $21.20. 1,229 shares of the company traded hands, compared to its average volume of 90,665. MediWound has a 52 week low of $12.78 and a 52 week high of $24.00. The business's 50-day simple moving average is $17.78 and its 200 day simple moving average is $17.73. The stock has a market capitalization of $229.08 million, a P/E ratio of -7.31 and a beta of 0.30.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in MDWD. GAMMA Investing LLC grew its stake in MediWound by 1,507.1% in the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,703 shares during the period. R Squared Ltd bought a new position in shares of MediWound in the 4th quarter worth about $32,000. Russell Investments Group Ltd. lifted its position in MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 1,162 shares during the period. Corebridge Financial Inc. lifted its position in MediWound by 17.1% during the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 665 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after acquiring an additional 999 shares in the last quarter. Institutional investors own 46.83% of the company's stock.
MediWound Company Profile
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
See Also
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
